Efficacy of intratympanic infiltration of N-acetyl cysteine in cisplatin ototoxicity
Licencia CC 4.0 (BY-NC-ND) © 2023 Revista Médica del Instituto Mexicano del Seguro Social..
Introduction: Currently there is no approved preventive or therapeutic pharmacological treatment to treat ototoxicity caused by cisplatin. N-acetyl cysteine (NAC) is a safe and inexpensive antioxidant that has been studied as an otoprotective alternative.
Objective: To describe the efficacy of intratympanic infiltration of NAC as prevention and treatment of ototoxicity induced in patients treated with cisplatin.
Material and methods: Open, longitudinal, prospective, randomized clinical trial in cancer patients treated with cisplatin who met the inclusion criteria. Out of the sample of 22 patients, 11 underwent intratympanic NAC infiltration and 11 were taken as a control group. It was performed an audiometry at the beginning and one month after on all patients.
Results: A sample of 22 patients with a mean age of 53 (±13) was collected. In our sample of 11 patients with infiltration in both ears, 1 ear showed improvement; on the other hand, in the control group that was not infiltrated, 4 showed an increase in hearing loss from mild to moderate in all 4 cases, 2 in the left ear and 2 in the right ear (Spearman's Rho = 0.93, p ≤ 0.001). Relative risk was of 1.22.
Conclusions: An association can be observed that intratympanic NAC could become an alternative for the prevention and treatment of cisplatin-induced ototoxicity.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:61 |
|---|---|
| Enthalten in: |
Revista medica del Instituto Mexicano del Seguro Social - 61(2023), Suppl 2 vom: 18. Sept., Seite S318-S322 |
| Sprache: |
Spanisch |
|---|
| Weiterer Titel: |
Eficacia de infiltración intratimpánica de N-acetilcisteína en ototoxicidad por cisplatino |
|---|
| Beteiligte Personen: |
Rosas-Gutiérrez, Goretti Del Carmen [VerfasserIn] |
|---|
| Themen: |
Acetilcisteína |
|---|
| Anmerkungen: |
Date Completed 30.11.2023 Date Revised 30.11.2023 published: Electronic Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM365073636 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365073636 | ||
| 003 | DE-627 | ||
| 005 | 20231226100911.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||spa c | ||
| 028 | 5 | 2 | |a pubmed24n1216.xml |
| 035 | |a (DE-627)NLM365073636 | ||
| 035 | |a (NLM)38016189 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a spa | ||
| 100 | 1 | |a Rosas-Gutiérrez, Goretti Del Carmen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy of intratympanic infiltration of N-acetyl cysteine in cisplatin ototoxicity |
| 246 | 3 | 3 | |a Eficacia de infiltración intratimpánica de N-acetilcisteína en ototoxicidad por cisplatino |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.11.2023 | ||
| 500 | |a Date Revised 30.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Licencia CC 4.0 (BY-NC-ND) © 2023 Revista Médica del Instituto Mexicano del Seguro Social. | ||
| 520 | |a Introduction: Currently there is no approved preventive or therapeutic pharmacological treatment to treat ototoxicity caused by cisplatin. N-acetyl cysteine (NAC) is a safe and inexpensive antioxidant that has been studied as an otoprotective alternative | ||
| 520 | |a Objective: To describe the efficacy of intratympanic infiltration of NAC as prevention and treatment of ototoxicity induced in patients treated with cisplatin | ||
| 520 | |a Material and methods: Open, longitudinal, prospective, randomized clinical trial in cancer patients treated with cisplatin who met the inclusion criteria. Out of the sample of 22 patients, 11 underwent intratympanic NAC infiltration and 11 were taken as a control group. It was performed an audiometry at the beginning and one month after on all patients | ||
| 520 | |a Results: A sample of 22 patients with a mean age of 53 (±13) was collected. In our sample of 11 patients with infiltration in both ears, 1 ear showed improvement; on the other hand, in the control group that was not infiltrated, 4 showed an increase in hearing loss from mild to moderate in all 4 cases, 2 in the left ear and 2 in the right ear (Spearman's Rho = 0.93, p ≤ 0.001). Relative risk was of 1.22 | ||
| 520 | |a Conclusions: An association can be observed that intratympanic NAC could become an alternative for the prevention and treatment of cisplatin-induced ototoxicity | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Acetilcisteína | |
| 650 | 4 | |a Acetylcysteine | |
| 650 | 4 | |a Cisplatin | |
| 650 | 4 | |a Cisplatino | |
| 650 | 4 | |a Ototoxicidad | |
| 650 | 4 | |a Ototoxicity | |
| 650 | 7 | |a Cisplatin |2 NLM | |
| 650 | 7 | |a Q20Q21Q62J |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Acetylcysteine |2 NLM | |
| 650 | 7 | |a WYQ7N0BPYC |2 NLM | |
| 700 | 1 | |a Fernández-Hernández, Juan Pablo |e verfasserin |4 aut | |
| 700 | 1 | |a Olea-González, Atzin Itaí |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revista medica del Instituto Mexicano del Seguro Social |d 2005 |g 61(2023), Suppl 2 vom: 18. Sept., Seite S318-S322 |w (DE-627)NLM156363798 |x 0443-5117 |7 nnns |
| 773 | 1 | 8 | |g volume:61 |g year:2023 |g number:Suppl 2 |g day:18 |g month:09 |g pages:S318-S322 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 61 |j 2023 |e Suppl 2 |b 18 |c 09 |h S318-S322 | ||